NCT00464178 · ADVERSE EVENTS

Adverse events

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2022-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 6 months
Other-event reporting threshold: 5%

period of study

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Drug Combination Overall Survival (OS) - Overall Survival is Calculated at the Time of the Screening Evaluation to Death From Any Cause.	0 / 5	0 / 5	Not reported / Not reported

Group identifiers: EG000: Drug Combination

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

period of study

event Groups

description
Overall Survival (OS) - Overall Survival is Calculated at the Time of the Screening Evaluation to Death From Any Cause.
id
EG000
other Num Affected
0
other Num At Risk
5
serious Num Affected
0
serious Num At Risk
5
title
Drug Combination

frequency Threshold

time Frame

6 months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice